Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWNNASDAQ:HCMNASDAQ:IMVTNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$6.33-3.8%$7.58$6.10▼$17.14$641.62M-1.241.09 million shs1.97 million shsHCMHUTCHMED$13.14-5.6%$14.68$11.51▼$21.79$2.29B0.55102,406 shs76,369 shsIMVTImmunovant$14.02-3.6%$16.38$12.72▼$34.47$2.38B0.751.21 million shs1.21 million shsMLTXMoonLake Immunotherapeutics$38.54-4.1%$38.43$31.42▼$58.26$2.47B1.31355,098 shs256,236 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals+2.02%-12.03%-7.58%-44.80%-58.88%HCMHUTCHMED-2.38%-7.94%+1.46%+5.45%-36.00%IMVTImmunovant+3.78%-4.40%-0.89%-24.77%-50.49%MLTXMoonLake Immunotherapeutics+4.45%-4.11%+15.13%-7.06%-1.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAWNDay One Biopharmaceuticals2.7722 of 5 stars4.61.00.00.02.52.50.0HCMHUTCHMED2.7797 of 5 stars3.04.00.00.03.00.01.9IMVTImmunovant2.6166 of 5 stars4.51.00.00.03.21.70.0MLTXMoonLake Immunotherapeutics3.1854 of 5 stars4.42.00.00.03.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 3.13Buy$30.57382.96% UpsideHCMHUTCHMED 2.00Hold$19.0044.60% UpsideIMVTImmunovant 2.90Moderate Buy$38.33173.42% UpsideMLTXMoonLake Immunotherapeutics 2.88Moderate Buy$81.67111.90% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, MLTX, IMVT, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$161.92M3.96N/AN/A$3.98 per share1.59HCMHUTCHMED$630.20M3.63$0.54 per share24.51$4.27 per share3.08IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.009.00N/AN/AN/AN/A7/29/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$36.01M-$1.89N/AN/AN/AN/A-15.54%-15.09%5/13/2025 (Estimated)Latest DAWN, MLTX, IMVT, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/A2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A14.6214.55HCMHUTCHMED0.072.812.68IMVTImmunovantN/A6.046.04MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%HCMHUTCHMED8.82%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%HCMHUTCHMED3.60%IMVTImmunovant5.90%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableIMVTImmunovant120169.86 million159.84 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableDAWN, MLTX, IMVT, and HCM HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy RatingMay 13 at 6:56 AM | tipranks.comMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 13 at 3:18 AM | finanznachrichten.deDecoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT InsightMay 13 at 12:08 AM | gurufocus.comMoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy RatingMay 12 at 7:54 PM | tipranks.comMoonLake Immunotherapeutics (MLTX) Strengthens Financial Position with New Funding | MLTX Stock NewsMay 12 at 5:24 PM | gurufocus.comMoonLake Immunotherapeutics Q1 2025 Earnings: EPS of -$0. ...May 12 at 5:24 PM | gurufocus.comMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a ...May 12 at 4:29 PM | gurufocus.comMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 12 at 4:00 PM | globenewswire.comGranahan Investment Management LLC Sells 36,196 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 12 at 6:35 AM | marketbeat.comBalyasny Asset Management L.P. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 11 at 5:31 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Acquired by Fred Alger Management LLCMay 10 at 8:33 AM | marketbeat.comCaption Management LLC Invests $670,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)May 9, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Buys 24,576 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)May 9, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Cut by BVF Inc. ILMay 6, 2025 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)May 2, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Should You Buy?May 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comBTIG Boosts Price Target for MoonLake Immunotherapeutics (MLTX) to $85 | MLTX Stock NewsApril 30, 2025 | gurufocus.comMoonLake Immunotherapeutics: Promising Developments and Financial Strength Justify Buy RatingApril 29, 2025 | tipranks.comMoonLake Immunotherapeutics: Promising Clinical Trials and Market Potential Drive Buy RatingApril 29, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, MLTX, IMVT, and HCM Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWN$6.33 -0.25 (-3.80%) As of 04:00 PM EasternDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.HUTCHMED NASDAQ:HCM$13.14 -0.78 (-5.60%) As of 04:00 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$14.02 -0.53 (-3.64%) As of 04:00 PM EasternImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$38.54 -1.64 (-4.08%) As of 04:00 PM EasternMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
